Loading organizations...
Magenta Therapeutics develops transformative medicines for patients undergoing hematopoietic stem cell transplantation (HSCT). The company leverages advanced stem cell science to enhance the safety and efficacy of this critical medical procedure. Its therapeutic strategies aim to optimize transplantation outcomes, addressing unmet needs in severe immune and blood diseases.
Established in 2015, Magenta Therapeutics was founded with the insight that stem cell transplantation, despite its curative potential, required substantial innovation. The company's vision centered on applying cutting-edge stem cell biology to overcome inherent risks and expand therapeutic applicability. Specific founders are not prominently detailed in its public inception story.
Magenta Therapeutics’ therapies target patients with severe immune and blood disorders who are candidates for stem cell transplant. The company’s overarching vision is to establish stem cell transplantation as a more accessible and successful treatment, broadening its therapeutic impact and improving patient quality of life.
Magenta Therapeutics has raised $151.0M across 3 funding rounds.
Magenta Therapeutics has raised $151.0M in total across 3 funding rounds.
Magenta Therapeutics has raised $151.0M in total across 3 funding rounds.
Magenta Therapeutics's investors include Eli Casdin, Access Industries, Be The Match BioTherapies, EcoR1 Capital, Eventide Asset Management, Watermill Asset Management, Atlas Venture, UP.Partners, Alexis A. Borisy, Google Ventures, Partners Innovation Fund.
Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines to enhance stem cell transplantation (HSCT) for patients with blood cancers, genetic diseases, and autoimmune disorders.[1][2][3] It builds therapies targeting conditioning and mobilization to make HSCT safer, more effective, and accessible, serving patients needing curative blood and immune resets while addressing limitations of traditional radiation and chemotherapy.[1][2][7] The company halted all programs in February 2023 due to resource constraints, leading to an 84% workforce reduction, significantly curbing its growth momentum.[7]
Magenta Therapeutics emerged from breakthroughs in stem cell biology, assembling a team of experts in stem cell biology, biotherapeutics, and transplant medicine to pioneer blood and immune reset therapies.[2] Founded as a private company before going public (NASDAQ: MGTA), it focused on an integrated pipeline for HSCT optimization, with early emphasis on clinical and preclinical candidates like MGTA-117, MGTA-145, and MGTA-45.[2][7] Pivotal moments included advancing Phase 1/2 trials for acute myeloid leukemia and myelodysplastic syndromes, and Phase 2 for sickle cell disease, before the 2023 strategic pivot to discontinue development amid high costs and timelines.[7]
Magenta rides the wave of advancing cell and gene therapies, where HSCT enables curative resets for immune and blood diseases amid growing demand for less toxic alternatives to conventional treatments.[2][3] Timing aligned with scientific progress in stem cell biology, but market forces like high development costs and clinical risks prompted its 2023 halt, highlighting biotech funding challenges.[7] It influenced the ecosystem by pioneering targeted conditioning, potentially paving the way for partners or acquirers in transplant medicine, though its reduced operations limit ongoing impact.[1][2]
Post-2023 restructuring, Magenta's pipeline is dormant, with no active trials or development, shifting focus to potential asset sales, partnerships, or wind-down amid biotech volatility.[7] Trends like precision gene editing and ADC innovations could revive interest in its CD45-targeted tech if acquired, evolving its legacy from developer to foundational IP contributor in HSCT.[1][4][7] Watch for strategic transactions tying back to its original mission of broader transplant access.
Magenta Therapeutics has raised $151.0M across 3 funding rounds. Most recently, it raised $52.0M Series C in April 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 9, 2018 | $52.0M Series C | Eli Casdin | Access Industries, Be The Match BioTherapies, EcoR1 Capital, Eventide Asset Management, Watermill Asset Management |
| May 1, 2017 | $50.0M Series B | Atlas Venture, UP.Partners | |
| Nov 1, 2016 | $49.0M Series A | Atlas Venture, Alexis A. Borisy | UP.Partners, Access Industries, Google Ventures, Partners Innovation Fund |